Source:http://linkedlifedata.com/resource/pubmed/id/17031069
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-10-19
|
pubmed:abstractText |
We investigated the effects of 4-(N-{1-[2-(4-cyanophenyl)ethyl]-4-hydroxypiperidin-4-ylmethyl}-N-methylamino)benzoic acid monohydrochloride (M58996), a novel analgesic, on persistent and neuropathic pain in rats. In the formalin test, oral M58996 (0.3 - 10 mg/kg) reduced nociceptive behaviors only in the late phase. In the neuropathic pain model, oral M58996 (1 - 10 mg/kg) attenuated mechanical allodynia and heat hyperalgesia in the nerve-injured paw without affecting normal responses of the uninjured paw. High doses (10 - 100 mg/kg) of oral M58996 did not influence normal motor function. Thus, M58996 had a wide dose range showing antinociceptive, antiallodynic, and antihyperalgesic effects without motor dysfunction. In addition, we studied the possible mechanisms involved in the M58996-induced antinociception. The antinociceptive effect of M58996 was reversed by intrathecal pertussis toxin, an inhibitor of the inhibitory- and other-GTP-binding protein (G(i/o) protein), but not by subcutaneous naloxone, an opioid-receptor antagonist. This effect was also reversed by intracerebroventricular or intrathecal tropisetron, a 5-hydroxytryptamine(3) (5-HT(3))-receptor antagonist, and intraperitoneal bicuculline, a gamma-aminobutyric acid(A) (GABA(A))-receptor antagonist. These results suggest that M58996 produces its antinociceptive effect by a pertussis toxin-sensitive G protein mechanism. In addition, the GABA released by the activation of supraspinal and/or spinal 5-HT(3) receptors is likely to contribute to the M58996-induced antinociception.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/4-Aminobenzoic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics,
http://linkedlifedata.com/resource/pubmed/chemical/Biogenic Monoamines,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, GABA
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1347-8613
|
pubmed:author |
pubmed-author:AkadaYasushigeY,
pubmed-author:KamiyaMasatsuguM,
pubmed-author:KatoKazuoK,
pubmed-author:KatoYutakaY,
pubmed-author:KurokawaMisaoM,
pubmed-author:MatsuuraKazuyukiK,
pubmed-author:MoriReikoR,
pubmed-author:NabaHiroyasuH,
pubmed-author:OgiharaTakuoT,
pubmed-author:SuzukiKazuhiroK,
pubmed-author:YamamotoIchiroI,
pubmed-author:YamasakiFumiakiF
|
pubmed:issnType |
Print
|
pubmed:volume |
102
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
205-12
|
pubmed:meshHeading |
pubmed-meshheading:17031069-4-Aminobenzoic Acid,
pubmed-meshheading:17031069-Administration, Oral,
pubmed-meshheading:17031069-Analgesics,
pubmed-meshheading:17031069-Animals,
pubmed-meshheading:17031069-Behavior, Animal,
pubmed-meshheading:17031069-Biogenic Monoamines,
pubmed-meshheading:17031069-Disease Models, Animal,
pubmed-meshheading:17031069-Dose-Response Relationship, Drug,
pubmed-meshheading:17031069-Male,
pubmed-meshheading:17031069-Motor Activity,
pubmed-meshheading:17031069-Pain,
pubmed-meshheading:17031069-Pain Measurement,
pubmed-meshheading:17031069-Piperidines,
pubmed-meshheading:17031069-Rats,
pubmed-meshheading:17031069-Rats, Wistar,
pubmed-meshheading:17031069-Receptors, GABA,
pubmed-meshheading:17031069-Sciatic Neuropathy
|
pubmed:year |
2006
|
pubmed:articleTitle |
Pharmacological profiles of the novel analgesic M58996 in rat models of persistent and neuropathic pain.
|
pubmed:affiliation |
Pharmaceutical Research Center, Mochida Pharmaceutical Co., Ltd., Japan. yakada@mochida.co.jp
|
pubmed:publicationType |
Journal Article
|